The mission of the Mayo Clinic Cancer Center is to promote and facilitate basic and clinical research on the incidence, etiology, and progression of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with cancer. Accordingly, Mayo Clinic Cancer Center research is broad and interdisciplinary, but highly cancer focused. Professional and public education activities are excellent and expansive, and clinical and psychosocial care of patients are of the highest quality and humanistic. These aggregate characteristics form the basis for our request for CCSG support and to continue our designation by the National Cancer Institute as a Comprehensive Cancer Center. The scientific objectives are met through twelve research programs whose members are drawn mostly from the principal site at Mayo Clinic Rochester, but also from components at Jacksonville and Scottsdale. The twelve research programs are: Genetic Epidemiology and Risk Assessment; Cancer Prevention and Control Cell Biology; Developmental Therapeutics; Cancer Imaging; Immunology and Immunotherapy; Gene and Virus Therapy; Prostate Cancer; Hematologic Malignancies; Neuro-oncology; Women's Cancer: and Gastrointestinal Cancer. This represents a net increase of five programs since our last review. Eighteen shared resources support the scientific initiatives. Scientific and fiscal administration of the Mayo Clinic Cancer Center is now stable, experienced, and robust, and we enjoy consistent and substantial support from Mayo Foundation leadership for our activities at all three Mayo sites. Plans for the future are guided by an uncompromising focus on creating and sustaining a Cancer Center that uses its own scientific capabilities and achievements and those of others for the gain of patients with cancer globally. Accordingly, substantial attention is being paid to research programs which elucidate the basic mechanisms of cancer etiology and optimize our ability to determine disease risk factors, thereby enabling better prevention, the development of better tools for early diagnosis, the design of novel therapeutics for stratified diseases, and the improvement of patients' quality of life, especially through neurobiologically based methods for palliation of pain.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-31
Application #
6949201
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2009-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
31
Fiscal Year
2005
Total Cost
$4,970,529
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications